All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Members of the FDA's arthritis drugs advisory committee on Friday voted 10-4 in favor of recommending that the agency approve a new drug application (NDA) for lesinurad, a gout drug developed by Astrazeneca plc subsidiary Ardea Biosciences Inc. to improve upon standard-of-care treatment for the condition.